Optimal Timing for Topical Lidocaine on Facial Skin

Formulation-Specific Guidelines

The American Academy of Pediatrics recommends liposomal 4% lidocaine cream (LMX4) reaches full effectiveness in 30 minutes without occlusion for intact facial skin procedures 1, 2
Liposomal 4% lidocaine (LMX4) provides adequate anesthesia without requiring occlusive dressing 1
The American Academy of Pediatrics notes that liposomal 4% lidocaine (LMX4) is faster than traditional EMLA preparations 1
EMLA cream (2.5% lidocaine/2.5% prilocaine) requires 60 minutes with occlusive dressing to reach full effectiveness 1, 4
Heat-activated systems have a shortened onset time of 10-20 minutes 1, 2

The Journal of the American Academy of Dermatology recommends not exceeding 4.5 mg/kg without epinephrine or 7.0 mg/kg with epinephrine in adults 5, 6
For children, the maximum safe dose is 1.5-2.0 mg/kg without epinephrine or 3.0-4.5 mg/kg with epinephrine 5, 6
The American Academy of Dermatology recommends reducing doses by 30% in infants under 6 months 7
Early warning signs of toxicity include circumoral numbness, facial tingling, and metallic taste at plasma concentrations of 5-10 μg/mL 8, 6

The American Academy of Pediatrics states that allergy to amide anesthetics is an absolute contraindication for facial application 1, 2
The Anaesthesia journal recommends using topical lidocaine with extreme caution in patients with cardiac disease, seizure disorders, hepatic impairment, or weighing less than 40 kg 8, 6
The American Academy of Pediatrics advises avoiding topical lidocaine on non-intact skin 1, 2